| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.3389/FENDO.2017.00116 |
| P8608 | Fatcat ID | release_5uqoasrnmjghtnatl6hsjqefr4 |
| P932 | PMC publication ID | 5461358 |
| P698 | PubMed publication ID | 28638367 |
| P50 | author | Sandro C. Esteves | Q38325634 |
| Peter Humaidan | Q54217726 | ||
| Thor Haahr | Q57069149 | ||
| Matheus Roque | Q88063269 | ||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology | Q24193015 | ||
| Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis | Q34312003 | ||
| The longer-term health outcomes for children born as a result of IVF treatment: Part I--General health outcomes | Q34330313 | ||
| Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases | Q38253309 | ||
| Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. | Q38355567 | ||
| The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors | Q38429206 | ||
| Segmented ART - The new era in ART? | Q38854810 | ||
| Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials | Q38876689 | ||
| Effects of perinatal, late foetal, and early embryonic insults on the cardiovascular phenotype in experimental animal models and humans | Q38947029 | ||
| Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study | Q39380673 | ||
| GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines | Q40672328 | ||
| Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience | Q41645905 | ||
| Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles | Q42166546 | ||
| P-values and reproductive health: what can clinical researchers learn from the American Statistical Association? | Q42726424 | ||
| Obstetric outcome in singletons after in vitro fertilization with cryopreserved/thawed embryos | Q43964590 | ||
| Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles | Q44695063 | ||
| Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. | Q46020786 | ||
| Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels | Q46129515 | ||
| 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study | Q46129525 | ||
| Perinatal outcomes of children born after frozen-thawed embryo transfer: a Nordic cohort study from the CoNARTaS group | Q46319575 | ||
| GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study | Q46370791 | ||
| A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists | Q46568123 | ||
| Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial | Q46913640 | ||
| 'Luteal coasting' after GnRH agonist trigger - individualized, HCG-based, progesterone-free luteal support in 'high responders': a case series | Q48565972 | ||
| Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. | Q48572942 | ||
| Cryopreserved embryo transfer is an independent risk factor for placenta accreta | Q48583809 | ||
| GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'. | Q48597751 | ||
| GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients | Q48623268 | ||
| International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. | Q48667199 | ||
| GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. | Q48668054 | ||
| A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study | Q48687403 | ||
| The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective | Q48794248 | ||
| Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study | Q59676551 | ||
| Large baby syndrome in singletons born after frozen embryo transfer (FET): is it due to maternal factors or the cryotechnique? | Q61847446 | ||
| Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol | Q87305772 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 116 | |
| P577 | publication date | 2017-06-07 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis | |
| P478 | volume | 8 |
| Q54958781 | Association Between Progesterone Elevation on the Day of Human Chronic Gonadotropin Trigger and Pregnancy Outcomes After Fresh Embryo Transfer in In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles. |
| Q58769667 | Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why |
| Q56346043 | Early stop of progesterone supplementation after confirmation of pregnancy in IVF/ICSI fresh embryo transfer cycles of poor responders does not affect pregnancy outcome |
| Q55116047 | Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. |
| Q64098391 | GnRH Agonist versus hCG Trigger in Ovulation Induction with Intrauterine Insemination: A Randomized Controlled Trial |
| Q52663984 | Individualized controlled ovarian stimulation in expected poor-responders: an update. |
| Q90400739 | Management Strategies for POSEIDON Groups 3 and 4 |
| Q90597789 | Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations |
| Q91796937 | Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population |
| Q91868092 | The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists |
Search more.